Lisha Wang1,2,3, Fei Ren4,5, Qifeng Wang4,5, Lee Ann Baldridge6, M Francesca Monn6, Kurt W Fisher6, Weiqi Sheng4,5, Xiaoyan Zhou4,5, Xiang Du4,5, Liang Cheng6. 1. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. wlisha@med.umich.edu. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wlisha@med.umich.edu. 3. Michigan Center for Translational Pathology, University of Michigan, 1400 E. Medical Center Drive, Ann Arbor, MI, 48109, USA. wlisha@med.umich.edu. 4. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. 5. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 6. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN, 46202, USA.
Abstract
INTRODUCTION: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. METHODS: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. RESULTS: In univariate analysis, TNM stage (p < 0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09-3.05, p = 0.021; HR 2.49, 95 % CI 1.51-4.12, p < 0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. CONCLUSIONS: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.
INTRODUCTION: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. METHODS: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancerpatients. RESULTS: In univariate analysis, TNM stage (p < 0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09-3.05, p = 0.021; HR 2.49, 95 % CI 1.51-4.12, p < 0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. CONCLUSIONS: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancerpatients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.
Authors: Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544
Authors: Jonathan A D Simpson; Ahmad Al-Attar; Nicholas F S Watson; John H Scholefield; Mohammad Ilyas; Lindy G Durrant Journal: Gut Date: 2010-07 Impact factor: 23.059
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Kristin Wallace; David N Lewin; Shaoli Sun; Clayton M Spiceland; Don C Rockey; Alexander V Alekseyenko; Jennifer D Wu; John A Baron; Anthony J Alberg; Elizabeth G Hill Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-16 Impact factor: 4.254
Authors: Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir Journal: Mol Diagn Ther Date: 2022-02-01 Impact factor: 4.074
Authors: Gerardo Botti; Giosuè Scognamiglio; Laura Marra; Antonio Pizzolorusso; Maurizio Di Bonito; Rossella De Cecio; Monica Cantile; Annarosaria De Chiara Journal: J Cancer Date: 2017-09-15 Impact factor: 4.207
Authors: Jonna Berntsson; Jakob Eberhard; Björn Nodin; Karin Leandersson; Anna H Larsson; Karin Jirström Journal: Oncoimmunology Date: 2018-06-11 Impact factor: 8.110